A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; BLI 1401 (Primary)
Indications Chronic myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions
Sponsors BioLite Inc

Most Recent Events

26 Feb 2024 Planned End Date changed from 1 Jun 2025 to 30 Jun 2026.
26 Feb 2024 Planned primary completion date changed from 1 Dec 2024 to 31 Dec 2025.
26 Feb 2024 Planned initiation date changed from 1 Jan 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight